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Abstract
The high prevalence of HIV infection among prisoners and pre-trial detainees, combined with overcrowding and
sub-standard living conditions sometimes amounting to inhuman or degrading treatment in violation of
international law, make prisons and other detention centres a high risk environment for the transmission of HIV.
Ultimately, this contributes to HIV epidemics in the communities to which prisoners return upon their release.
We reviewed the evidence regarding HIV prevalence, risk behaviours and transmission in prisons. We also reviewed
evidence of the effectiveness of interventions and approaches to reduce the risk behaviours and, consequently, HIV
transmission in prisons.
A large number of studies report high levels of risk behaviour in prisons, and HIV transmission has been
documented. There is a large body of evidence from countries around the world of what prison systems can do to
prevent HIV transmission. In particular, condom distribution programmes, accompanied by measures to prevent the
occurrence of rape and other forms of non-consensual sex, needle and syringe programmes and opioid
substitution therapies, have proven effective at reducing HIV risk behaviours in a wide range of prison
environments without resulting in negative consequences for the health of prison staff or prisoners.
The introduction of these programmes in prisons is therefore warranted as part of comprehensive programmes to
address HIV in prisons, including HIV education, voluntary HIV testing and counselling, and provision of
antiretroviral treatment for HIV-positive prisoners. In addition, however, action to reduce overcrowding and
improve conditions in detention is urgently needed.
Review
Forgotten prisoners: a global crisis of conditions in
detention
A global crisis of conditions in detention is being wit-
nessed by the United Nations Special Rapporteur on
Torture and Other Forms of Cruel, Inhuman or Degrad-
ing Treatment or Punishment. The Special Rapporteur
exercises a mandate entrusted to him by the highest
human rights body of the United Nations (UN), the
Human Rights Council, to investigate the situation of
torture and ill-treatment in all countries of the world.
He presents reports about his findings and recommen-
dations to the General Assembly in New York and the
Human Rights Council in Geneva.
In addition to conducting research and dealing with a
high number of individual complaints, since 2005, he
has carried out fact-finding missions to roughly 20
countries in all regions of the world, among them Geor-
gia, Mongolia, China (including the autonomous regions
of Tibet and Qinjang), Nepal, Jordan, Paraguay, Togo,
Nigeria, Sri Lanka, Indonesia, Denmark (including
Greenland), the Republic of Moldova (including Trans-
nistria), Equatorial Guinea, Uruguay, Kazakhstan,
Jamaica and Papua New Guinea.
Since torture usually takes place behind closed doors,
the Special Rapporteur spends a significant amount of
time during the fact-finding missions in prisons, remand
centres, police lock-ups, psychiatric institutions, and
special detention facilities for women, children, asylum
seekers, migrants and people who use drugs. By asses-
sing conditions of detention in each country he visits,
the UN Special Rapporteur on Torture also acts as a de
facto special rapporteur on prison conditions.
Governments have no legal obligation to invite the
UN Special Rapporteur to their countries, and several
governments, notably in the Middle East, have refused
investigations into torture and ill-treatment in their
countries. Others have invited the Rapporteur and later
cancelled or “postponed” their invitations, often at the
last minute: the USA (in respect of the detention facil-
ities in Guantánamo Bay), the Russian Federation,
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r e f e r e n c ea r et h er e a s o nf o rt h er e l u c t a n c eo fs t a t e st o
receive the Special Rapporteur. These terms include the
possibility of: carrying out unannounced visits to places
of detention; bringing a team of experts into prisons,
including a forensic expert, with the necessary equip-
ment to document torture and ill-treatment (e.g., photo
and video cameras); and conducting private (unsuper-
vised) interviews with detainees [1].
The conclusions of the UN Special Rapporteur are
alarming: with very few exceptions (such as Denmark
and Greenland) [2], torture in detention facilities is
practiced in most of the countries he has visited, often
in a routine, widespread or even systematic manner,
such as in Nepal [3] and Equatorial Guinea [4]. In some
countries, including Sri Lanka [5] and Jordan [6], the
Special Rapporteur observed that the methods of torture
used are simply shocking and remind one of times
forgotten.
But for most of the detainees interviewed by the UN
Special Rapporteur, their experience of torture during
the first days or weeks of police custody aimed at
extracting a confession or information was little com-
pared with the continued suffering of detainees. They
had endured this suffering during many months of
police custody with no more than a place to sit on the
dirty floor (e.g., in Equatorial Guinea, Jamaica [7] and
Papua New Guinea [8], during many years of pre-trial
detention virtually forgotten by prosecutors, judges and
the outside world (e.g., in Nigeria [9], Paraguay [10] and
Uruguay [11]), and during decades of incarceration in
overcrowded prisons, often in isolation or under intoler-
able conditions on death row and similar strict confine-
ment for long-term prisoners (e.g., Mongolia [12],
Georgia [13] and Moldova [14]).
In China, an unbearable pressure of re-education and
brainwashing is exerted on the entire prison population,
ranging from special re-education through labour camps
to remand centres and correctional institutions, until
the will and dignity of the person concerned is finally
broken [15]. In his 2009 report to the UN General
Assembly, the Special Rapporteur concluded that “in
many countries of the world, places of detention are
constantly overcrowded, and filthy locations, where
tuberculosis and other highly contagious diseases are
rife [, ...] lack the minimum facilities necessary to allow
for a dignified existence [16].”
In other words, conditions of detention in many coun-
tries amount to inhuman or degrading treatment in vio-
lation of international law. There is a veritable global
crisis of conditions of detention. Without understanding
this background, it is not possible to appreciate the
challenges posed by HIV in detention, to which we now
turn.
Two epidemics: HIV and incarceration
HIV hit prisons early and it hit them hard. The rates of
HIV infection among prisoners in many countries are
significantly higher than those in the general population.
Coincident with the HIV/AIDS epidemic, many coun-
tries have been experiencing a significant increase in the
incarcerated population, often as a result of an intensifi-
c a t i o no ft h ee n f o r c e m e n to fd r u gl a w si na ne f f o r tt o
limit the supply and use of illegal drugs. Each of the two
“epidemics” - HIV and incarceration - has affected the
other.
For the purposes of this paper, the term, “prisoner”,i s
used broadly to refer to adult and juvenile males and
females detained in criminal justice and correctional
facilities: during the investigation of a crime; while
awaiting trial; after conviction and before sentencing;
and after sentencing. Although the term does not for-
mally cover persons detained for reasons relating to
immigration or refugee status, and those detained with-
out charge, most of the considerations in this paper
apply to them, as well. The term, “prison”,i su s e dt o
refer to all criminal justice and correctional facilities.
The HIV epidemic in prisons
HIV surveillance has been the most common form of
HIV research in prison, although this has largely been
restricted to high-income countries. Data from low- and
middle-income countries are more limited [17]. Even
within high-income countries, the precise number of
prisoners living with HIV is difficult to estimate. Rates
of HIV infection reported from studies undertaken in a
single prison or region may not accurately reflect HIV
prevalence in prisons across the country.
Nevertheless, reviews of HIV prevalence in prison
have shown that HIV infection is a serious problem, and
one that requires immediate action [18]. In most coun-
tries, HIV prevalence rates in prison are several times
higher than in the community outside prisons, and this
is closely related to the rate of HIV infection among
people who inject drugs in the community and the pro-
portion of prisoners convicted for drug-related offences
[19]. In other countries, particularly in sub-Saharan
Africa, elevated HIV prevalence rates in prisons reflect
the high HIV prevalence rates in the general population
[20]. Everywhere, the prison population consists of indi-
viduals with greater risk factors for contracting HIV
(and HCV and TB) compared with the general popula-
tion outside of prisons. Such characteristics include
injecting drug use, poverty, alcohol abuse, and living in
minority communities with reduced access to healthcare
services [21].
Studies have shown HIV prevalence that ranges from
zero in a young male offenders institution in Scotland
[22] and among prisoners in Iowa, United States, in
1986 [23], to 33.6% in an adult prison in Catalonia,
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for women in New York City [25]. As early as 1988,
about half of the prisoners in Madrid [26] and 20% of
prisoners in New York City tested HIV positive [27].
More recent reports show that HIV prevalence rates
remain high in prisons in North America [28-30] and
western Europe, although they have decreased in coun-
tries like Spain that have introduced comprehensive
HIV interventions in prisons, including needle and syr-
inge programmes and methadone maintenance treat-
ment [31].
In the countries of central and eastern Europe and the
former Soviet Union, HIV prevalence is particularly high
in prisons in Russia and Ukraine, but also in Lithuania,
Latvia and Estonia. In Russia, by late 2002, the regis-
tered number of people living with HIV/AIDS in the
penal system exceeded 36,000, representing approxi-
mately 20% of known HIV cases. In Latin America, pre-
valence among prisoners in Brazil and Argentina was
reported to be particularly high, with studies showing
rates of between 3% and more than 20% in Brazil and
from 4% to 10% in Argentina.
Rates reported from studies in other countries, includ-
ing Mexico, Honduras, Nicaragua and Panama are also
high [32]. In India, one study found that the rates were
highest among female prisoners, at 9.5% [33]. In Africa,
a study undertaken in Zambia found a rate of 27% [34].
The highest HIV prevalence reported among a national
prison population was in South Africa, where estimates
put the figure as high as 41.4% [32]. Conversely, some
countries report zero prevalence; most of these are in
north Africa or the Middle East [32].
The HIV epidemic in prisonsi sn o to c c u r r i n ga l o n e :
prevalence rates of viral hepatitis in prisons are even
higher than HIV rates [35,36]. In particular, while the
World Health Organization (WHO) estimates that
about 3% of the world’s population has been infected
with the hepatitis C virus (HCV), [37] estimates of the
prevalence of HCV in prisons range from 4.8% in an
Indian jail [38] to 92% in two prisons in northern Spain
[39,40].
Tuberculosis (TB) is also common: in some countries,
it has been estimated that it is 100 times more common
in prisons than in the community [41]. Wherever TB is
evident in prisons, it is a significant health problem.
Sub-standard prison living conditions, including over-
crowding, poor ventilation, poor lighting and inadequate
nutrition, make the attempts to control the spread of
TB in prisons more difficult. TB incidence rates are
therefore very high in many prisons. Moreover, prisons
in geographically disparate places (from Thailand to
New York State to Russia) have reported high levels of
drug-resistant TB. TB poses a substantial danger to the
health of all prisoners, staff and the community outside
prisons. Prisoners living with HIV are at particular risk.
HIV infection is the most important risk factor for the
development of TB, and TB is the main cause of death
among people living with HIV. TB mortality in prisons
is elevated [42].
Within prison populations, certain groups have higher
levels of infection. In particular, the prevalence of HIV
and HCV infection among women tends to be higher
than among men [18].
The epidemic of incarceration
Coincident with the emergence of HIV and later HCV,
many countries have been experiencing a significant
increase in the size of their incarcerated population. As
of 1998, more than 8 million people were held in penal
institutions throughout the world, either as pre-trial
detainees or having been convicted and sentenced. As of
December 2008, more than 9.8 million people were
incarcerated [43]. If prisoners in “administrative deten-
tion” in China are included, the total was more than
10.6 million. Between 2005 and 2008, prison populations
rose in 71% of countries [43]. Each year, some 30 mil-
lion people enter and leave prison establishments.
The USA has the highest prison population rate in the
world (748 per 100,000 of the national population), fol-
l o w e db yR u s s i a( 5 9 5 ) ,R w a n d a( 5 9 3 )a n dan u m b e ro f
countries in eastern Europe and in the Caribbean.
Countries with particularly low rates include Liechten-
stein (28), Nepal (24), Nigeria (29) and India (32). On
average, the prison population rate is 145 per 100,000.
Certain regions, such as the Caribbean, eastern Europe,
central Asia and southern Africa, have much higher
rates, while others, such as northern and western Eur-
ope, western Africa and Oceania (with few exceptions)
have much lower average rates [43].
In the absence of internationally agreed minimum
space requirements for detainees, it is difficult to mea-
sure the level of overcrowding, but overcrowding is a
common problem. The best proxy indicator is the offi-
cial occupancy rate, i.e., the percentage of the actual
number of prisoners in relation to the official maximum
capacity of the prison system as a whole. Although
states can easily manipulate these statistics by simply
enlarging the official maximum capacity, some 60% of
all countries in the world report an occupancy rate of
more than 100%, which means that they hold more pris-
oners than the maximum capacity. In 16 countries, pri-
marily in Africa, the occupancy rate exceeds 200% [44].
There are various reasons for such extreme over-
crowding, including, above all: the lack of non-custodial
measures for dealing with crime, (i.e., incarceration is
regarded as the only measure for dealing with suspected
criminals rather than as a measure of last resort); the
criminalization of behaviours seen as socially undesir-
able by many legislators (sex work, drug-related
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functioning of the criminal justice system in many
countries.
The best indicator for the failure of the criminal jus-
tice system is the percentage of pre-trial detainees com-
pared with the total prison population. According to
international law, pre-trial detention should be the
exception and is only permissible for the shortest period
of time (usually no longer than a few months) [45]. In
reality, persons suspected of petty and other criminal
offences who lack money for bribes or bail often spend
many years in pre-trial detention, forgotten by prosecu-
tors and judges. In many countries in Africa (Liberia,
Mali, Benin, Niger, Congo Brazzaville, Nigeria, Burundi
and Cameroon), Latin America (Haiti, Bolivia, Paraguay,
Honduras and Uruguay), and Asia (Bangladesh, India,
Pakistan and the Philippines), pre-trial detainees com-
prise more than 60% of the total prison population. It is,
therefore, not surprising that high occupancy rates and
pre-trial detention rates correlate in many countries,
such as in Haiti before the earthquake in January 2010,
Benin, Bangladesh, Burundi, Pakistan and Mali [43].
In many parts of the world, the growth in prison
populations (and often the resulting increase in over-
crowding) has been the result of an intensification of
the enforcement of drug laws in an effort to limit the
supply and use of illegal drugs. As a result of the large
number of prisoners convicted for drug-related offences,
the demographic and epidemiological characteristics of
the incarcerated population are significantly different
today in many countries from what they were two dec-
ades ago. Consistent with the nature of the crimes for
which they are convicted, incarcerated individuals have
a high prevalence of drug dependence, mental illness
and infectious diseases, including HIV [46].
By choosing mass imprisonment as the main response
to the use of drugs, countries have created a de facto
policy of incarcerating more and more individuals with
HIV infection [47]. Many prisoners serve short sen-
tences, and recidivism to prison is common. Conse-
quently, HIV-positive people (and at-risk individuals)
move frequently between prisons and their home com-
munities. For example, in the Russian Federation, each
year, 300,000 prisoners, many of whom are living with
HIV, viral hepatitis and/or TB, are released from prisons
[48]. Most prisoners will return to their home commu-
nities within a few years. The high degree of mobility
between prison and community means that communic-
able diseases and related illnesses transmitted or exacer-
bated in prison do not remain there. When people
living with HIV and HCV (and/or TB) are released from
incarceration, prison health issues necessarily become
community health issues.
Risk behaviours in prison
Injecting drug use
For people who inject drugs, imprisonment is a com-
mon event, with studies from a large number of coun-
tries reporting that between 56% and 90% of people
who inject drugs had been imprisoned at some stage
[49,50]. Multiple prison sentences are more common for
prisoners who inject drugs than for other prisoners [51].
Some people who used drugs prior to imprisonment
discontinue their drug use while in prison. However,
many carry on using on the inside, often with reduced
frequency and amounts [51], but sometimes maintaining
the same level of use [52]. Prison is also a place where
drug use is initiated, often as a means to release tension
and to cope with being in an overcrowded and often
violent environment [53,54].
Injecting drug use in prison is of particular concern
given the potential for transmission of HIV, TB and
viral hepatitis. Those who inject drugs in prisons often
share needles and syringes and other injecting equip-
ment, which is an efficient way of transmitting HIV
[55]. A large number of studies from countries around
the world report high levels of injecting drug use,
including among female prisoners [56,57]. Although
more research has been carried out on injecting drug
use in prisons in high-income countries, studies from
low-income and middle-income countries have found
similar results. In Iran, for example, about 10% of pris-
oners are believed to inject drugs, and more than 95%
of them are reported to share needles [58]. Injecting
drug use has also been documented in prisons in coun-
tries in eastern Europe and central Asia [59-62], and
there are also reports of injecting drug use in prisons in
Latin America [63] and sub-Saharan Africa [64].
Consensual and non-consensual sexual activity
It is challenging to obtain reliable data on the preva-
lence of sexual activities in prisons because of the many
methodological, logistical and ethical challenges of
undertaking a study of sexual activity in prisons. Sex,
with the exception of authorized conjugal visits, violates
prison regulations. Many prisoners decline to participate
in studies because they claim not to have engaged in
any high-risk behaviour [65]. Prisoners who do partici-
pate may be too embarrassed to admit to engaging in
same-sex sexual activity for fear of being labelled as
weak or gay, and they may fear punitive measures.
Despite these challenges, studies undertaken in a large
number of countries show that consensual and non-con-
sensual sex does occur in prisons. Estimates of the propor-
tion of prisoners who engage in consensual same-sex
sexual activity in prison vary widely, with some studies
reporting relatively low rates of 1% to 2% [66,67], while
other studies report rates between 4% and 10% [59,68-70]
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[56,72].
Some same-sex sexual activity occurs as a conse-
quence of sexual orientation. However, most men who
have sex in prisons do not identify themselves as homo-
sexuals and may not have experienced same-sex sex
prior to their incarceration [73].
Distinguishing coerced sex from consensual sex in
prison can be difficult: prisoner sexual violence is a
complex continuum that includes a host of sexually
coercive (non-consensual) behaviours, including sexual
harassment, sexual extortion and sexual assault. It can
involve prisoners and/or staff as perpetrators. Rape in
prison can be unimaginably vicious and brutal. Gang
assaults are not uncommon, and victims may be left
beaten, bloody and, in the most extreme cases, dead
[18]. Yet overtly violent rapes are only the most visible
and dramatic form of sexual abuse behind bars. Many
victims of sexual violence in prison may have never
been explicitly threatened, but they have nonetheless
engaged in sexual acts against their will, believing they
had no choice [74].
Most studies on incidence of sexual violence in prison
have focused on male victims in the United States, typi-
cally reporting high rates of “sexual aggression” (11% to
40%), while reporting lower rates of “completed rape” of
usually between 1% and 3% [18]. Lower levels of sexual
violence than in the United States have been reported in
some other developed countries. International prison
research has revealed that sexual violence occurs in pris-
ons around the world [74,75].
In prisons, with the exception of countries in which
injecting drug use is rare, sexual activity is considered
to be a less significant risk factor for HIV transmis-
sion than sharing of injecting equipment. Neverthe-
less, sexual activities can place prisoners at risk of
contracting HIV and other sexually transmitted infec-
tions (STIs). Violent forms of unprotected anal or
vaginal intercourse, including rape, carry the highest
risk of HIV transmission [76]. Environmental or
population conditions or factors that affect the risk of
HIV and other STI transmission through sexual activ-
ity in prison include: the prevalence of infection in
the particular prison or sub-section of the prison; the
prevalence of various forms of sexual activity; and
whether commodities, such as condoms, lubricant
and dental dams, are provided and accessible to
prisoners.
Other risk factors
Additional risk factors for blood-borne infections
include the sharing or re-use of tattooing and body pier-
cing equipments, sharing of razors for shaving, blood-
sharing/"brotherhood” rituals and the improper steriliza-
tion or re-use of medical or dental instruments.
Factors related to the prison infrastructure and prison
management contribute indirectly to vulnerability to
HIV and other infections. They include overcrowding,
violence, gang activities, lack of protection for vulnerable
or young prisoners, prison staff that lack training or may
be corrupt, and poor medical and social services
HIV transmission resulting from risk behaviours in prisons
The prevalence of risk behaviours, coupled with the lack
of access to prevention measures in many prisons, can
result in frighteningly quick spread of HIV. There were
early indications that extensive HIV transmission could
occur in prisons. In Thailand, the first epidemic out-
break of HIV in the country likely began among people
who inject drugs in the Bangkok prison system in 1988
[77]. Since then, a large number of studies from coun-
tries in many regions of the world have reported HIV
and/or HCV seroconversion within prisons or shown
that a history of imprisonment is associated with preva-
lent and incident HIV and/or HCV and/or hepatitis B
virus (HBV) infection among people who inject drugs
[18].
HIV infection has been significantly associated with a
history of imprisonment in countries in western and
southern Europe (including among female prisoners
[78-83]), but also in Russia [84], Canada [85], Brazil
[86], Iran [87] and Thailand [88]. Using non-sterile
injecting equipment in prison was found to be the most
important independent determinant of HIV infection in
a number of studies [18].
The strongest evidence of extensive HIV transmission
through injecting drug use in prison has emerged from
documented outbreaks in Scotland [89], Australia [90],
Russia [91] and Lithuania [92]. Outbreaks of HIV have
also been reported from other countries [93].
Well-documented evidence exists for STI intra-prison
transmission through sexual contacts among prisoners,
for example in Russia and in Malawi [91,73]. Evidence
also exists of HIV intra-prison transmission through
sexual contacts among prisoners. In one United States
study of HIV transmission in prison, sex between men
accounted for the largest proportion of prisoners who
contracted HIV inside prison [94].
International human rights and the responsibility of
prison systems
By its very nature, imprisonment involves the loss of the
r i g h tt ol i b e r t y .H o w e v e r ,p r i s o n e r sr e t a i nt h e i ro t h e r
rights and privileges, except those necessarily removed
or restricted by the fact of their incarceration. In parti-
cular, prisoners, as every other person, have a right to
the highest attainable level of physical and mental
health: the state’s duty with respect to health does not
end at the gates of prisons [95].
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tial HIV prevention measures and to treatment equiva-
lent to that available outside is a violation of prisoners’
right to health in international law. Moreover, it is
inconsistent with international instruments that deal
with rights of prisoners, prison health services and HIV/
AIDS in prisons, including the United Nations’ Basic
Principles for the Treatment of Prisoners [96], the
WHO Guidelines on HIV Infection and AIDS in Prisons
[97], and the International Guidelines on HIV/AIDS and
Human Rights [98].
A c c o r d i n gt ot h eW H Og u i d e l i n e s ,“[a]ll prisoners
have the right to receive health care, including preven-
tive measures, equivalent to that available in the com-
munity without discrimination, in particular with
respect to their legal status or nationality” [97].
The International Guidelines on HIV/AIDS and
Human Rights identifies the following specific action in
relation to prisons [98]:
Prison authorities should take all necessary mea-
sures, including adequate staffing, effective surveil-
lance and appropriate disciplinary measures, to
protect prisoners from rape, sexual violence and
coercion. Prison authorities should also provide pris-
oners (and prison staff, as appropriate), with access
to HIV-related prevention information, education,
voluntary testing and counselling, means of preven-
tion (condoms, bleach and clean injection equip-
ment), treatment and care and voluntary
participation in HIV-related clinical trials, as well as
ensure confidentiality, and should prohibit manda-
tory testing, segregation and denial of access to
prison facilities, privileges and release programmes
for HIV-positive prisoners. Compassionate early
release of prisoners living with AIDS should be
considered.
Preventing and responding to HIV and other infections in
prisons: a human rights and public health imperative
Two elements are key to preventing and responding to
HIV and other infections, such as hepatitis B and C and
TB, in prisons:
￿ Introducing comprehensive prevention measures
￿ Providing treatment, care and support, including
antiretroviral treatment for HIV, and ensuring conti-
nuity of care between prisons and the community.
In addition, improving prison conditions and under-
taking other prison reforms and reducing prison popula-
tions is also essential.
Introducing comprehensive prevention measures
Information and education
Education is an essential precondition to the implemen-
tation of HIV prevention measures in prisons. The
World Health Organization’sG u i d e l i n e so nH I VI n f e c -
tion and AIDS in Prisons recommends that both prison-
ers and prison staff be informed about ways to prevent
HIV transmission [97]. Written materials should be
appropriate for the educational level in the prison popu-
lation. Furthermore, prisoners and staff should partici-
pate in the development of educational materials.
Finally, peer educators can play a vital role in educating
other prisoners.
However, information and education alone are not
sufficient responses to HIV in prisons. A few evaluations
have indicated improvements in levels of knowledge and
self-reported behavioural change as a result of prison-
based educational initiatives [18]. But education and
counselling are not of much use to prisoners if they do
not have the means (such as condoms and clean inject-
ing equipment) to act on the information provided.
HIV testing and counselling
HIV testing and counselling (HTC) is important for two
reasons: as part of an HIV prevention programme (it
gives those who may be engaging in risky behaviours
information and support for behaviour change); and as a
w a yt od i a g n o s et h o s el i v i n gw i t hH I Va n do f f e rt h e m
appropriate treatment, care and support.
In practice, HTC in prisons is often available only on
demand of prisoners, but in some systems, HTC is easily
available. In some other systems, HTC is undertaken
routinely or is even compulsory. There is evidence sug-
gesting that mandatory HIV testing and segregation of
HIV-positive prisoners is costly, inefficient and can have
negative health consequences for segregated prisoners
[18].
Consistent with HTC guidance developed for prison-
ers [99], detainees and people undergoing compulsory
drug treatment, countries should ensure that all people
in these settings have easy access to HTC programmes
a ta n yt i m ed u r i n gt h e i rs t a y .T h e ys h o u l db ei n f o r m e d
about the availability of services, both at the time of
their admission and regularly thereafter. In addition,
healthcare providers in these settings should offer HTC
to all during medical examinations, and recommend
HTC in the event of signs, symptoms or medical condi-
tions that could indicate HIV infection, including TB, to
assure appropriate diagnosis and access to necessary
HIV treatment, care and support as indicated. Efforts to
increase access to HTC should not be undertaken in
isolation, but as part of comprehensive HIV pro-
grammes aimed at improving healthcare, decreasing
stigma and discrimination, protecting confidentiality of
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comprehensive HIV prevention, treatment, care and
support.
All forms of coercion must be avoided and HIV test-
ing must always be done with informed consent, ade-
quate pre-test information or counselling, post-test
counselling, protection of confidentiality, and referral to
services.
Provision of condoms and prevention of rape, sexual
violence and coercion
Recognizing the fact that sex occurs in prisons and
given the risk of disease transmission that it carries, pro-
viding condoms has been widely recommended. As early
as 1991, 23 of 52 prison systems surveyed by the World
Health Organization provided condoms to prisoners
[100]. Today, many more prison systems make condoms
available, including most systems in western Europe,
Canada and Australia, some prisons in the United
States, parts of eastern Europe and central Asia, and
countries like Brazil, South Africa, Iran and Indonesia
[101].
T h e r ei se v i d e n c et h a tc o n d o m sc a nb ep r o v i d e di na
wide range of prison settings - including in countries in
which same-sex activity is criminalized - and that pris-
oners use condoms to prevent HIV infection during sex-
ual activity when condoms are easily accessible in prison
(i.e., when prisoners can pick them up confidentially,
without having to ask for them) [101]. No prison system
allowing condoms has reversed its policy, and none has
reported security problems or any other relevant major
negative consequences. In particular, it has been found
that condom access represents no threat to security or
operations, does not lead to an increase in sexual activ-
ity, and is accepted by most prisoners and correctional
officers once it is introduced [101].
However, in some countries where legal sanctions
against sodomy exist in the community outside prison,
and where there are deeply held beliefs and prejudices
against homosexuality, introduction of condoms into
prisons as an HIV prevention measure may have to be
particularly well prepared. This can be done through
education and information about the purpose of the
introduction of condoms, as well as initiatives to coun-
ter the stigma that people engaging in same-sex activity
face.
Finally, while providing condoms in prisons is impor-
tant, it is not enough to address the risk of sexual trans-
mission of HIV. Violence, including sexual abuse, is
common in many prison systems. In many prison sys-
tems, HIV prevention depends as much or more on
prison and penal reform than on condoms. Prison and
penal reform need to greatly reduce the prison popula-
tions so that the few and often underpaid guards are
able to protect the vulnerable prisoners from violence -
and sexual coercion.
The Guidelines on HIV Infection and AIDS in Prisons
[97] and the International Guidelines on HIV/AIDS and
Human Rights [98] highlight the reality that prison
authorities are responsible for combating aggressive sex-
ual behaviour, such as rape, exploitation of vulnerable
prisoners and all forms of prisoner victimization by pro-
viding adequate staffing, effective surveillance, disciplin-
ary sanctions, and education, work and leisure
programmes. Structural interventions, such as better
lighting, shower and sleeping arrangements, are also
needed.
Conjugal visits should also be allowed and an appro-
priate section of the prison outfitted for this purpose.
Condoms should be available in that section, and pris-
oners should be allowed to carry condoms back to the
main prison, thus allowing for further discreet
distribution.
Needle and syringe programmes
The first prison needle and syringe programme (NSP)
was established in Switzerland in 1992. Since then,
NSPs have been introduced in more than 60 prisons in
11 countries in Europe and central Asia. In some coun-
tries, only a few prisons have NSPs. However, in Kyrgyz-
stan and Spain, NSPs have been rapidly scaled up and
operate in a large number of prisons [102].
G e r m a n yi st h eo n l yc o u n t r yi nw h i c hp r i s o nN S P s
have been closed. At the end of 2000, NSPs had been
successfully introduced in seven prisons, and other pris-
ons were considering implementing them. However,
since that time, six of the programmes have been closed
as a result of political decisions by the newly elected
conservative state governments, without consultation
with prison staff. Since the programmes closed, prison-
ers have gone back to sharing injecting equipment and
to hiding it, increasing the likelihood of transmission of
HIV and HCV [103]. Staff have been among the most
vocal critics of the governments’ decision to close down
the programmes, and have lobbied the governments to
reinstate the programmes [103].
In most countries with prison NSPs, implementation
has not required changes to laws or regulations in order
to allow it. Across the 11 countries, various models for
the distribution of sterile injecting equipment have been
used, including anonymous syringe dispensing machines,
hand-to-hand distribution by prison health staff and/or
non-government organization workers, and distribution
by prisoners trained as peer outreach workers [102].
Systematic evaluations of the effects of NSPs on HIV-
related risk behaviours and of their overall effectiveness
in prisons have been undertaken in 10 projects. These
evaluations and other reports demonstrate that NSPs
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in men and women’s prisons, prisons of all security
levels, and small and large prisons. Providing sterile nee-
dles and syringes is readily accepted by people who
inject in prisons and contributes to a significant reduc-
tion of syringe sharing over time. It also appears to be
effective in reducing resulting HIV infections [102].
At the same time, there is no evidence to suggest that
prison-based NSPs have serious, unintended negative
consequences. In particular, they do not lead to
increased drug use or injecting; nor are they used as
weapons [102]. Evaluations have found that NSPs in
prisons actually facilitate referral of people who use
drugs to drug dependence treatment programmes
[104,105].
Studies have shown that important factors in the suc-
cess of prison NSPs include easy and confidential access
to the service, providing the right type of syringes and
building trust with the prisoners accessing the pro-
gramme [102]. For example, in Moldova, only a small
number of prisoners accessed the NSP when it was
located within the healthcare section of the prison. It
was only when prisoners could obtain sterile injecting
equipment from fellow prisoners, trained to provide
harm-reduction services, that the amount of equipment
distributed increased significantly [106].
Following an exhaustive review of the international
evidence, WHO, the United Nations Office on Drugs
and Crime (UNODC) and the Joint United Nations Pro-
gramme on HIV/AIDS (UNAIDS) in 2007 recom-
mended that “prison authorities in countries
experiencing or threatened by an epidemic of HIV infec-
tions among people who inject drugs should introduce
and scale up NSPs urgently” [102].
Bleach programmes
Programmes providing bleach or other disinfectants for
sterilizing needles and syringes to reduce HIV transmis-
sion among people who inject drugs in the community
were first introduced in San Francisco, United States, in
1986 [107]. Such programmes have received support,
particularly in situations where opposition to NSPs in
the community or in prisons has been strongest.
The number of prison systems that make bleach or
other disinfectants available to prisoners has continued
to grow, but already in 1991, 16 of 52 prison systems
surveyed made them available, including in Africa and
central America [100]. Today, bleach or other disinfec-
tants are available in many prison systems, including in
Australia, Canada, Indonesia, Iran and some systems in
eastern Europe and central Asia [102].
Evaluations of bleach programmes in prisons have
shown that distribution of bleach or other disinfectants
is feasible and does not compromise security [102].
H o w e v e r ,W H Oh a sc o n c l u d e dt h a tt h e“evidence
supporting the effectiveness of bleach in decontamina-
tion of injecting equipment and other forms of disinfec-
tion is weak” [108]. While the efficacy of bleach as a
disinfectant for inactivating HIV has been shown in
laboratory studies, field studies have cast “considerable
doubt on the likelihood that these measures could ever
be effective in operational conditions” [108]. Moreover,
studies assessing the effect of bleach on HCV prevalence
did not find a significant effect of bleach on HCV sero-
conversion [109,110].
For these reasons, bleach programmes are inadequate
to address the risks associated with sharing of injecting
equipment and are regarded as a second-line strategy to
NSPs. WHO, UNODC and UNAIDS have recom-
mended that bleach programmes be made available in
prisons where “authorities continue to oppose the intro-
duction of NSPs despite evidence of their effectiveness,
and to complement NSPs” [102].
Opioid substitution therapy and other drug dependence
treatment
Since the early 1990s, and mostly in response to raising
HIV rates among people who inject drugs in the com-
munity and in prison, there has been a marked increase
in the number of prison systems providing opioid sub-
stitution therapy (OST) to prisoners. Today, prison sys-
tems in nearly 40 countries offer OST to prisoners,
including most systems in Canada and Australia, some
systems in the United States, and most of the systems in
the 15 “old” European Union (EU) member states [111],
as well as Iran, Indonesia and Malaysia [112]. In Spain,
according to 2009 data, 12% of all prisoners received
OST [112]. However, in most other prison systems, cov-
erage is much lower.
OST programmes are also provided in some of the
states that joined the EU more recently (including Hun-
g a r y ,M a l t a ,S l o v e n i aa n dP o land), although they often
remain small and benefit only a small number of prison-
ers in need [113]. A small number of systems in eastern
Europe and central Asia have also started OST pro-
grammes (such as Moldova and Albania) or are plan-
ning to do so soon [113].
Reflecting the situation in the community, most prison
systems make OST available in the form of methadone
maintenance treatment (MMT). Buprenorphine mainte-
nance treatment is available only in a small number of
systems, including in Australia and some European
countries [114,115].
Generally, drug-free treatment approaches continue to
dominate interventions in prisons in most countries
[116]. OST remains controversial in many prison sys-
tems, even in countries where it accepted as an effective
intervention for opioid dependence in the community
outside of prisons. Prison administrators have often not
been receptive to providing OST due to philosophical
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whether the provision of such therapy will lead to diver-
sion of medication, violence and/or security breaches
[117].
A recent comprehensive review showed that OST, in
particular with MMT, is feasible in a wide range of
p r i s o ns e t t i n g s[ 1 1 3 ] .A si st h ec a s ew i t hO S Tp r o -
grammes outside prisons, those inside prisons are effec-
tive in reducing the frequency of injecting drug use and
associated sharing of injecting equipment if a sufficient
dosage is provided (more than 60 mg per day) and treat-
ment is provided for longer periods of time (more than
six months) or even for the duration of incarceration
[118].
In addition, evaluations of prison-based MMT found
other benefits, both for the health of prisoners partici-
pating in the programmes, and for prison systems and
the community. For example, re-incarceration is less
likely among prisoners who receive adequate OST, and
OST has been shown to have a positive effect on institu-
tional behaviour by reducing drug-seeking behaviour
and thus improving prison safety [113]. While prison
administrations have often initially raised concerns
about security, violent behaviour and diversion of
methadone, these problems have not emerged or have
been addressed successfully where OST programmes
have been implemented [113].
WHO, UNODC and UNAIDS have recommended
that “prison authorities in countries in which OST is
available in the community should introduce OST pro-
grammes urgently and expand implementation to scale
as soon as possible” [113].
In contrast to OST, other forms of drug dependence
treatment have not usually been introduced in prison
with HIV prevention as one of their objectives. There-
fore, there is little data on their effectiveness as an HIV
prevention strategy [113].
Nevertheless, good quality, appropriate and accessible
treatment has the potential of improving prison security,
as well as the health and social functioning of prisoners,
and might reduce re-offending. Studies have demon-
strated the importance of providing ongoing treatment
and support and of meeting the individual needs of pris-
oners, including female prisoners, younger prisoners and
prisoners from ethnic minorities [113]. Given that many
prisoners have severe problems related to the use of ille-
gal drugs, it would be unethical not to provide people in
prison with access to a wide range of drug treatment
options [119].
Therefore, WHO, UNODC and UNAIDS have recom-
mended that, in addition to providing OST, prison
authorities also provide a range of other drug depen-
dence treatment options for prisoners with problematic
drug use, in particular for other substances, such as
amphetamine-type stimulants. However, because data
on the effectiveness of these other forms of treatment as
an HIV prevention strategy are lacking, they recom-
mended that evaluations of their effectiveness in terms
of reducing drug injecting and needle sharing should be
undertaken [113].
While drug-free or abstinence-based treatment should
be considered as a necessary element of comprehensive
prison drug services, such programmes alone are insuffi-
cient to address the multiple health risks posed by
injecting drug use and HIV transmission in prisons.
In some countries, including Cambodia, China, Indo-
nesia, Laos, Malaysia, Myanmar, Thailand and Vietnam,
people who use drugs can face coerced “treatment” and
“rehabilitation” in compulsory drug detention centres,
which results in many human rights abuses [31]. In
many of these centres, the services provided are of poor
quality and do not accord with either human rights or
scientific principles. Treatment in these facilities takes
the form of sanction rather than therapy, and relapse
rates are very high [120]. These centres should be closed
and replaced with drug treatment that works.
Other measures to reduce the demand for drugs
In addition to drug dependence treatment, other strate-
gies to reduce the demand for drugs can also assist
efforts to prevent HIV transmission in prisons. However,
it is important to note from the outset that such efforts
are unlikely to eliminate drug use in prisons. In fact,
even prison systems that have devoted large financial
resources to such efforts have not been able to eliminate
drug use [113]. Therefore, such efforts cannot replace
the other measures that we have described, but rather
should be undertaken to complement them.
Provision of information on drugs and drug use On
its own, the provision of information on drugs and drug
use has not been found to change drug use behaviour.
However, substantial and correct information is neces-
sary to make healthy choices, and all drug dependence
programmes should include an education component
[121].
Work, study and other activities Research shows that
one of the reasons why some prisoners take drugs
when they are in prison is to combat boredom and
alienation, and to promote relaxation [122]. This sug-
gests a need for more purposeful activities in prisons.
Providing prisoners with opportunities to work and/or
study while in prison, or to take part in activities, such
as sports, theatre and spiritual and cultural enhance-
ment aimed at providing people with challenging and
healthy ways to employ their time, can have a positive
effect on risky behaviours, particularly when comple-
mented by appropriate drug use prevention education
(which might include both information and life skills
provision).
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also important. Life skills are the abilities for adaptive
and positive behaviour that enable individuals to deal
effectively with the demands and challenges of everyday
life. These include: self-awareness, empathy, communi-
cation skills, interpersonal skills, decision-making skills,
problem-solving skills, creative thinking, critical think-
ing, and coping with emotions and stress. Such personal
and social competencies, together with appropriate
information about drugs and drug use, help people
make healthier choices.
Establishing so-called “drug-free” units Another strat-
egy to reduce the demand for drugs used by an increas-
ing number of prison systems, mainly in resource-rich
countries, is to establish so-called “drug-free” units.
Typically, “drug-free” units or wings are separate living
units within a prison that focus on limiting the availabil-
ity of drugs, and are populated with prisoners who have
voluntarily signed a contract promising to remain drug
free. In some instances, they focus solely on drug inter-
diction through increased searching, while some systems
provide a multi-faceted approach combining drug inter-
diction measures with treatment services.
“Drug-free” units could assist efforts to combat the
s p r e a do fH I Vi np r i s o ni ft h e yr e s u l t e di nd e c r e a s e d
drug use, particularly injecting drug use. There is some
evidence from a small number of studies that “drug-
free” units do indeed significantly reduce levels of drug
use among residents in these units [113]. Such units
appeal to a large number of prisoners, including prison-
ers who do not have any drug problems and want to
live in a “drug-free” environment. However, the studies
do not say anything about whether “drug-free” units
appeal to, and are successful in retaining, the most pro-
blematic drug users, in particular prisoners who inject
drugs. Currently, there is therefore no data on the effec-
tiveness of drug-free units as an HIV prevention strategy
[113].
Measures to reduce the supply of drugs
A broad range of search and seizure techniques and
procedures can be used in an attempt to reduce the
availability of drugs in prisons. These supply reduction
measures include: random searches by security person-
nel; prison staff and visitor entry/exit screening and
searches; drug detection dogs; closed-circuit monitoring;
perimeter security measures (netting over exercise yards,
higher internal fences to prevent projectiles, rapid
response vehicles patrolling the prison perimeter); pur-
chasing of goods from approved suppliers only; intelli-
gence analysts at every institution; drug detection
technologies (such as ion scanners and X-ray machines);
modifications to the design and layout of visiting areas
(use of fixed and low-level furniture); and drug testing
(also called urinalysis).
Many prison systems, particularly in resource-rich
countries, have placed considerable emphasis on these
measures to reduce the supply of drugs. While such
measures are not aimed at addressing HIV in prisons,
they may result in unintended consequences for HIV
(and HCV) prevention efforts. Drug interdiction mea-
sures may assist HIV prevention efforts by reducing the
supply of drugs and injecting in prisons. At the same
time, they could make such efforts more difficult.
For example, many resource-rich prison systems regu-
larly or randomly test prisoners’ urine for illegal drug
use. Prisoners who are found to have consumed illegal
drugs can face penalties. From a public health perspec-
tive, concerns have been raised that these programmes
may increase, rather than decrease, prisoners’ risk of
HIV infection. There is evidence that implementing
such programmes may contribute to reducing the
demand for and use of cannabis in prisons [123,124].
However, such programmes seem to have little effect
on the use of opiates [114,125]. In fact, there is evidence
that a small number of people may switch to injectable
drugs to avoid detection of cannabis use through drug
testing [113]. Cannabis is traceable in urine for much
longer (up to one month) than drugs administered by
injecting, such as heroin and other opiates. Some pris-
oners choose to inject drugs rather than risk the penal-
ties associated with smoking cannabis simply to
minimize the risk of detection and punishment. Given
the scarcity of sterile needles and the frequency of nee-
dle sharing in prison, the switch to injecting drugs may
have serious health consequences for prisoners.
Generally, despite the fact that many prison systems
make substantial investments in drug supply reduction
measures, there is little solid and consistent empirical
evidence available to confirm their efficacy in reducing
levels of drug use. In particular, there is no evidence
that these measures may lead to reduced HIV risk [113].
Prison systems facing resource constraints should
therefore not implement costly measures, such as drug
detection technologies and drug testing, that may use
up a substantial amount of resources that could other-
wise be used for managing HIV/AIDS in prisons.
Instead, they should focus on the proven and cost-effec-
tive HIV prevention measur e st h a tw eh a v ed e s c r i b e d
and on efforts to improve prison conditions and work-
ing conditions and pay for prison staff, without whom
other drug supply reduction strategies are unlikely to be
successful [113,122].
Other measures
Detection and treatment of sexually transmitted
infections Early detection and treatment of sexually
transmitted infections (STIs) is important because these
infections increase the chances of an individual acquir-
ing and transmitting HIV [122].
Jürgens et al. Journal of the International AIDS Society 2011, 14:26
http://www.jiasociety.org/content/14/1/26
Page 10 of 17Post-exposure prophylaxis There is evidence from stu-
dies in the community that provision of antiretroviral
drugs to prevent HIV infection after unanticipated sex-
ual exposure might be beneficial [126]. This has resulted
in recommendations that post-exposure prophylaxis
(PEP) be made available to persons seeking care less
than 72 hours after exposure to blood, genital secretions
or other potentially infectious body fluids of a person
known to be HIV infected when that exposure repre-
sents a substantial risk for transmission. PEP refers to a
set of services to prevent the infection from developing
in the exposed person. These include: first aid care;
counselling and risk assessment; HIV testing following
informed consent; and depending on risk assessment,
the provision of short-term (28 days) antiretroviral
drugs. If indicated, antiretroviral drugs should be
initiated as soon as possible after exposure [126].
Recommendations have also been formulated for other
scenarios in which PEP may be offered [127]. In particu-
lar, use of PEP has been widely encouraged for victims
of sexual assault [128-130].
In the first documented use of PEP in the prison set-
ting anywhere in the world, 46 prisoners in Australia
were offered PEP, and 34 elected to receive it, but only
eight completed the full PEP course. The study con-
cluded that PEP administration in prisons is feasible,
but that special consideration of prison circumstances is
necessary to ensure accurate risk assessment, considera-
tion of ongoing risk behaviours, prompt initiation of
therapy, good compliance and adequate follow up [131].
WHO, UNODC and UNAIDS have recommended
that prison systems should make PEP available in cases
in which it could reduce the risk for HIV transmission
after exposure to HIV. Specific guidelines for the use of
PEP in prisons should be developed by correctional
health services to improve the administration of PEP in
the prison setting [101].
Controlling the spread of TB TB poses a substantial
danger to the health of all prisoners, prison staff and the
community outside prisons. Prisoners living with HIV
are at particular risk. HIV infection is the most impor-
tant risk factor for the development of TB, and TB is
the main cause of death among people living with HIV.
For these reasons, in addition to improving conditions
in prisons that fuel the spread of TB, prisons must
develop and implement comprehensive TB control pro-
grammes, which should be coordinated with or inte-
grated in national TB control programmes and work
closely with the HIV programme [121].
Hepatitis B vaccination Hepatitis B is easily spread in
prisons. In contrast to HIV, the risk of infection can be
reduced through the administration of a vaccine. All
staff and prisoners should have easy access to free hepa-
titis B vaccination. In addition, consideration should be
given to providing hepatitis A vaccination to prisoners
at risk [121].
Hepatitis C prevention In addition to contributing to
reduced risk of HIV transmission in prisons, most of
the measures just described also contribute to redu-
cing the risk of hepatitis C virus (HCV) transmission.
However, HCV is much more easily spread than HIV,
including through sharing of shavers and tooth-
brushes, as well as through tattooing and body pier-
cing [121]. It is therefore important that prisons make
information available to all prisoners and staff about
the risks of HCV transmission in prison, and educate
them about the ways to reduce that risk. In addition,
shavers and toothbrushes should be made available to
p r i s o n e r ss ot h a tt h e yd on o th a v et os h a r et h e mw i t h
fellow prisoners; and prisons should consider imple-
menting measures to reduce the spread of HCV
through tattooing and body piercing, such as making
sterile tattooing equipment available to prisoners
[121].
Protecting staff
Protection of staff from infectious diseases is a duty and
also part of good prison management. High rates of
HIV and other infectious diseases in prisons make them
more stressful places in which to work. High rates of
staff turnover, whether due to ill health or lack of job
satisfaction have a major impact on the management of
prisons [121].
It is essential that staff receive initial and ongoing
training to enable them to do their duties in a healthy
and safe manner, and to feel secure themselves and be
able to give prisoners appropriate guidance and support.
This training should enable them to anticipate and man-
age situations in which they may be exposed to HIV or
hepatitis. Staff should also bet r a i n e di nt h es a f ep r o v i -
sion of first aid.
When on duty, relevant prison staff should have
access to personal protective equipment, such as latex
gloves, masks for use in mouth-to-mouth resuscitation,
protective eyewear, soap, and mirrors for use in search-
ing. Staff should also have free access to hepatitis B
vaccination.
Safe work procedures should be developed, including
searching procedures. Post-exposure procedures also
must be in place. The procedures should address
immediate action, follow-up action, record keeping and
confidentiality. Finally, staff should have access to
appropriate professional counselling and follow-up ser-
vices, including PEP, after possible and definite expo-
sures to blood and body fluids. Finally, ample space,
adequate lighting and optimum staffing levels are
important to ensure safe work practices, and measures
are required to improve the general work conditions of
prison staff.
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of prisoners (and prison staff), and all must be handled
equally - as if they were HIV positive, both for safety
reasons and in order to avoid discrimination [121].
Providing treatment, care and support, including
provision of antiretroviral treatment for HIV
In addition to providing comprehensive HIV prevention
programmes, national governments have a responsibility
to provide prisoners with treatment, care and support
equivalent to that available to other members of the
community.
Health in prison is a right guaranteed in international
law, as well as in international rules, guidelines and
covenants [95]. The right to health includes the right to
medical treatment and to preventive measures and to
standards of health care equivalent to those available in
the community. As it was stated in April 1996 by
UNAIDS to the United Nations Commission on Human
Rights at its 52
nd session [132]:
HIV/AIDS in prisons remains a difficult and contro-
versial subject.... Often there are not enough
resources to provide basic health care in prisons,
much less HIV/AIDS programmes. Yet the situation
is an urgent one. It involves the rights to health,
security of the person, equality before the law and
freedom from inhuman and degrading treatment....
With regard to effective HIV/AIDS prevention and
care programmes, prisoners have a right to be pro-
vided the basic standard of medical care available in
the community.
Effective HIV treatment in prison settings
The right to medical care in prisons includes the provi-
sion of antiretroviral therapy (ART) in the context of
comprehensive HIV care [133]. The advent of combina-
tion ART has significantly decreased mortality due to
HIV infection and AIDS in countries around the world
where ART has become accessible. There has been a
parallel decrease in the mortality rate among incarcer-
ated individuals in prison systems in those countries.
Providing access to ART for those in need in prisons
is a challenge, but it is necessary and feasible. Studies
have documented that, when provided with care and
access to medications, prisoners respond well to antire-
troviral treatment [134]. The right to enjoyment of the
highest attainable standard of physical and mental
health, in concert with the principle of equivalence, dic-
tates that prisoners should have access to the same stan-
dard of care available to people outside prisons.
As ART has increasingly become available in develop-
ing countries and countries in transition, and as coun-
tries are moving towards the goal of universal access to
HIV prevention, treatment, care and support, it is
critical to ensure that treatment also becomes available
to all prisoners who need it. Ensuring continuity of care
from the community to the prison and back to the com-
munity, as well as continuity of care within the prison
system, is a fundamental component of successful treat-
ment scale-up efforts. Treatment discontinuation for
short or long periods of time may happen upon arrest
and detention in police cells, within the prison system
when prisoners are transferred to other facilities or have
to appear in court, and upon release. Each of these
situations should be addressed and mechanisms estab-
lished to ensure uninterrupted ART [135,136]. Particular
attention should be devoted to discharge planning and
linkage to community aftercare.
In addition, the following actions will facilitate conti-
nuity of treatment [133]:
￿ Prison departments must have a place within the
national HIV/AIDS coordinating committees, and prison
issues need to be part of the agreed HIV/AIDS action
framework and country-level monitoring and evaluation
system.
￿ Prison departments need to be involved in all
aspects of treatment scale up, from applications for
funding (to ensure that funds are specifically earmarked
for prisons), to development, implementation, and mon-
itoring and evaluation of treatment roll-out plans.
￿ The ministry responsible for health and the ministry
responsible for the prison system should collaborate clo-
sely, recognizing that prison health is public health.
￿ Policies or guidelines should be developed specifying
that people with HIV or AIDS are allowed to keep their
HIV medication upon them, or are to be provided with
their medication, upon arrest and incarceration, and at
any time that they are transferred within the system or
to court hearings. Police and prison staff need to be
educated about the importance of continuity of
treatment.
Prison healthcare: the need for increased funding and a
new model
Health services in prison settings are most often sub-
standard and underfunded, and short of staff, of essen-
tial medications, of equipment and of appropriate infra-
structures. Often, health services in prison settings work
in complete isolation from the general healthcare sys-
tem, hampering the quality of healthcare and making
continuity of care a challenge. HIV/AIDS, HCV and TB
have exacerbated existing problems in healthcare provi-
sion in prisons. Prison healthcare budgets must reflect
the growing needs of the prison population. Prison
healthcare should be recognized as an integral part of
the public health sector, and evolve from its present
reactive “sick call” model into a proactive system that
emphasizes early disease detection and treatment, health
promotion and disease prevention.
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fulfill the core functions of public health services within
prisons, i.e., to: assess the health status of prisoners;
have an effective surveillance system for infectious and
chronic diseases; undertake health promotion efforts;
have coordinated actions to prevent diseases and inju-
ries; protect the health of prisoners; and evaluate the
effectiveness, accessibility and quality of health services
[137]. Addressing prisoners’ health needs will contribute
to the prisoner’s rehabilitation and successful reintegra-
tion into the community [121].
Transferring control of prison health
In the longer term, transferring control of prison health
to public health authorities could have a positive impact
on HIV/AIDS care in prison [138]. In the vast majority
of prison systems in the world, healthcare is provided by
the same ministry or department responsible for prison
administration, not by the ministry or department
responsible for healthcare. Prisons were not designed
and are generally not equipped to deal with prisoners
infected with chronic, potentially fatal diseases, such as
HIV/AIDS, hepatitis and tuberculosis. They do not have
adequate staffing levels, adequate staff training or ade-
quate equipment to meet the health needs of prisoners
suffering from these diseases.
The authority and influence of prison authorities may
compromise healthcare professionals’ ethical obligations.
Trust and confidence are crucial to an effective, ethical
relationship between patient and healthcare provider.
When health services for prisoners are “captured”
within, or subservient to, the prison administration, it is
unlikely that prisoners will trust or have confidence in
the healthcare providers. This lack of trust contributes
to sub-standard healthcare for prisoners [95].
Experience in a range of prison systems has shown
that healthcare in prisons can be delivered more effec-
tively by public health authorities than by prison man-
agement. This has the advantage of strengthening the
link between health in the community and health in
prisons [136,138,139]. Some countries have already
introduced such a change in prison health administra-
tion. Norway was one of the first. In France, where
prison health was transferred to the Ministry of Health
in 1994, a positive impact is already evident [139]. Each
prison in France is twinned with a public hospital.
Special attention should be given to women prisoners
As women prisoners are fewer than males, the health
services provided for women are sometimes minimal or
second rate. With the advent of HIV/AIDS, a new pro-
blem has arisen for women prisoners. Women prisoners
need the same preventive measures and the same level
of care, treatment and support as male prisoners. Preg-
nant prisoners need access to the full range of preven-
tion of mother to child transmission interventions. In
addition, there is a need for initiatives that acknowledge
that the problems encountered by women in the correc-
tional environment often reflect, and are augmented by,
their vulnerability and the abuse many of them have suf-
fered outside prison. The task of protecting women pris-
oners from HIV transmission and of providing those
living with HIV with care, treatment and support there-
fore presents different - and sometimes greater - chal-
lenges than that of dealing with HIV infection in male
prisoners [140].
Conclusions
M u c hc a nb ed o n et oa d d r e s st h ep r o b l e m sl i n k e dt o
HIV and other infections in prisons by taking action in
the areas that we have outlined. In the medium- and
longer-term, however, it will be essential to take action
to improve prison conditions and reduce overcrowding.
Prison conditions are integrally linked to prison health,
and have the potential to affect the health of prisoners
in positive or negative ways.
Sub-standard living conditions and overcrowding, as
described at the beginning of this article, can increase
the risk of HIV transmission among prisoners by pro-
moting and encouraging drug use in response to bore-
dom or stress (most often involving unsafe injecting
practices) and by enabling prison violence, fighting, bul-
lying, sexual coercion and rape. They can also have a
negative impact on the health of prisoners living with
HIV by: increasing their exposure to infectious diseases,
such as TB and hepatitis; housing them in unhygienic
and unsanitary environments; confining them in spaces
that do not meet the minimum requirements for size,
natural lighting and ventilation; limiting access to open-
air and to educational, social or work activities; and fail-
ing to provide them with access to proper healthcare,
diet, nutrition and/or clean drinking water, and basic
hygiene [121]. A comprehensive programme of prison
reform based on the international human rights stan-
dards would do much to improve sub-standard living
conditions and, ultimately, to reduce the spread of HIV.
In addition, taking measures to reduce prison popula-
t i o n si se s s e n t i a l .I nt h es h o r tt e r m ,o v e r c r o w d i n gc a n
be reduced by amnesties, reviewing the legality of deten-
tion status so that those held unlawfully can be released,
and removing groups inappropriately held, such as those
prisoners with mental disorders.
In the medium and long term, there are two potential
solutions to overcrowding: increasing the capacity of the
prison system; or reducing the number of prisoners.
The first solution is very costly, and many countries do
not have the additional financial resources required to
expand their prison systems in ways that respect basic
human rights standards or could put those resources to
better use. Reducing imprisonment and pre-trial
Jürgens et al. Journal of the International AIDS Society 2011, 14:26
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Page 13 of 17detention is the better solution. Prison should only be
used as a place of last resort. In all other cases, alterna-
tives to custody should be used. A range of community-
based pre-trial and sentencing options and programmes
of supervised early release can help to ensure that
prison is used as a last resort and for the shortest time.
A good strategy is to adopt official government targets
for reducing prison overcrowding [121].
The overuse of incarceration of people who use drugs
is of particular concern. In many countries, a significant
percentage of the prison population is comprised of
individuals who are convicted of offences directly related
to their own drug use (i.e., those incarcerated for the
possession of small amounts of drugs for personal use,
and those convicted of petty crimes specifically to sup-
port drug habits). The incarceration of significant num-
bers of people who use drugs increases the likelihood of
drug use inside prisons, as well as unsafe injecting prac-
tices and the risk of transmission of HIV and other
blood-borne diseases.
Many of the problems created by HIV infection and
by drug use in prisons could be reduced if alternatives
to imprisonment are implemented, particularly in the
context of drug-related crimes. As early as 1987, the
World Health Organization, in a statement from the
first Consultation on Prevention and Control of AIDS in
Prisons, said that “[g]overnments may ... wish to review
their penal admission policies, particularly where drug
abusers are concerned, in the light of the AIDS epi-
demic and its impact on prisons” [141].
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